AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$CLYM

Thomas Stephen Basil sold $1.4M of CLYM

Thomas Stephen Basil sold 100,000 shares of Climb Bio, Inc. (CLYM) at $13.67 ($1.37M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thomas Stephen Basil
Published Sep 17, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CLYM
Bearish
medium confidence
Mentioned
$CLYM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLYMBearishLow
01

Why it matters

The director's sale may be interpreted by the market as a bearish cue, but the modest size limits impact.

02

Market read

Insider sale provides fresh data for traders monitoring Climb Bio; likely modest price effect.

03

What to watch

Potential upcoming clinical data releases or financing events that could offset the sell signal.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑09‑15

Background

SEC Form 4 filing discloses insider transactions; required to be reported within two business days.

Company-level read

Ticker impact

$CLYMBearishMedium confidence
Context

Director Thomas Stephen Basil sold 100,000 shares of Climb Bio for $1.37M via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

potential short‑term downside pressure

Evidence & confidence

The sale size ($1.4M) is modest but the insider is a director; market may interpret as a negative signal.

Market effects

Sector

Limited impact; biotech sector may see slight sentiment drag from insider sell.

Regional

Minimal, primarily affects US biotech investors.

Global

Low, confined to Climb Bio shareholders.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not reflect any negative outlook.

Key entities

  • Company
    Climb Bio, Inc.

    Biotech firm developing therapies for rare diseases.

  • Individual
    Thomas Stephen Basil

    Director of Climb Bio who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CLYM insider trading history →

Related articles

SEP 3
$CLYMMedAI 8/10

Climb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing prolonged half-life and durable suppression of targets, supporting every-12-week dosing. The treatment was well-tolerated. CLYM116 is being advanced in the Phase 2 NAVIGATE-2 trial for IgA nephropathy, with initial data expected in 2027. The company reported Q2 2026 net income of $1.9M and $239.2M in cash. CLYM stock rose 1.55% to $15.05 on Wednesday.

rttnews.com2 min
SEP 3
$CLYMMedAI 8/10

Why is Climb Bio stock sliding today?

Climb Bio (CLYM) stock fell 7% to $14.00 in pre-market trading after releasing Phase 1 clinical data for CLYM116, showing near-complete APRIL protein suppression and sustained IgA reductions. The decline follows a 'buy the rumor, sell the news' pattern, with investors taking profits after the data release. The company's Phase 2 trial data is not expected until 2027, contributing to the pullback. The broader market showed modest gains, with the S&P 500, Dow Jones, and Nasdaq up 0.3%, 0.6%, and 0.

investing.com2 min
SEP 3
$CLYMMedAI 8/10

Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing a 29-day half-life, 90% APRIL suppression, and 60-75% IgA suppression. The drug was well-tolerated. Phase 2 trial data is expected in H1 2027, with Phase 3 initiation planned for 2027. The company will host a webcast on September 3.

finanznachrichten.de2 min
SEP 3
$CLYMHighAI 8/10

Climb Bio stock surges 17% on positive drug trial results

Climb Bio, Inc. (CLYM) shares rose 17% after reporting positive Phase 1 trial results for CLYM116, its anti-APRIL monoclonal antibody. The drug showed near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression, with a half-life of 29 days. The trial enrolled 46 subjects and reported no serious adverse events. The company plans to present additional data in Q4 2026 and anticipates Phase 2 trial results in H1 2027.

investing.com2 min
AUG 6
$CLYMMed

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2

SEC EDGAR 8-K6 min